Validea's guru fundamental report highlights Johnson & Johnson (JNJ) as a top performer under its Partha Mohanram-based P/B Growth Investor model, achieving an 88% rating. This model identifies low book-to-market stocks with sustained growth potential. JNJ, a large-cap in Biotechnology & Drugs, passed 8 of 9 criteria for this growth strategy, notably failing on Research and Development to Assets, with the 88% score signaling 'some interest' from this academic-derived investment approach.
Johnson & Johnson (JNJ) screens favorably under Validea's Partha Mohanram P/B Growth Investor model, achieving a score of 88%, which indicates analytical interest in the stock. This model specifically identifies low book-to-market stocks with fundamental characteristics suggesting sustained future growth. JNJ, a large-cap in the Biotechnology & Drugs industry, passed 8 out of 9 core tests, demonstrating strength in key areas like Return on Assets, Cash Flow from Operations, and stability in both ROA and sales. This suggests strong current profitability and operational efficiency. However, the analysis pinpoints a critical failure on the 'Research and Development to Assets' criterion. For a company in a sector heavily reliant on innovation, this specific weakness could be a significant concern, potentially signaling underinvestment in its future growth pipeline relative to its substantial asset base.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
